By Chimnonso Onyekwelu LLB, lawyer and ANH researcher
Once viewed as a childhood condition, Attention Deficit Hyperactivity Disorder (ADHD) is now being diagnosed in adults at striking rates, affecting around 3.5% of the global adult population. Since the pandemic, prescriptions have surged—up 18% year-on-year in the UK and 30% among Americans aged 20 to 39. At first glance, this looks like progress. But a more unsettling question sits beneath the headlines: are we finally recognising those long overlooked, or are we simply pathologising the pressures and distractions of everyday life?
Access to care remains uneven, with long waiting lists and limited specialist support leaving many adults undiagnosed. Yet running alongside this is a quieter, more troubling trend. The rising overuse of stimulant medication. A Swedish study found 7.6% of adults were prescribed more than 150% of the recommended maximum dose, with 3.4% exceeding 200%. Meanwhile, self-diagnosis is flourishing across social media, and private clinics increasingly offer rapid assessments and same-day prescriptions. The result? A growing number of otherwise healthy adults being labelled and medicated for issues that may actually be linked to modern lifestyle and diet, stress, burnout, and digital overload rather than a clinical disorder.
Public perception is shifting just as quickly. In the US, one in four adults now believe they have undiagnosed ADHD; in England, it’s one in twenty. As diagnostic thresholds blur and prescribing pathways accelerate, the risks of misuse and diversion rise in tandem. ADHD is a genuine and often distressing condition that warrants appropriate care. But the sharp rise in adult diagnoses and medication use suggests we may be overlooking a significant public-health blind spot.
In this article, we unpack what’s driving this surge, examine the hidden risks of long-term stimulant use, and explore the often-ignored root causes of attention difficulties—alongside balanced, holistic strategies that support focus and resilience without defaulting to medication.
The rapid rise in adult ADHD diagnoses did not happen in isolation. The first shift came from within psychiatry itself. With the move from DSM-IV to DSM-5, the diagnostic criteria for ADHD broadened: the age of symptom onset was extended, fewer symptoms were required, and co-occurring conditions such as autism were no longer exclusionary. These changes opened the door to a much larger adult population. UK data show this clearly—between 2000 and 2018, adult ADHD diagnoses increased by almost 2000%, while stimulant prescriptions rose by nearly 5000% in men aged 18–29. The intention was improved recognition, but the effect was an expanded and increasingly ambiguous diagnostic category.
Alongside this clinical expansion came a cultural shift in how people interpret attention, motivation, and overwhelm. Social media platforms such as TikTok, Instagram, and YouTube have reframed ordinary human experiences such as forgetfulness, disorganisation and emotional burnout, as symptoms of ADHD. On TikTok alone, millions of posts promote quick “symptom lists,” with one study finding that 52% of the most-viewed ADHD videos were misleading. Algorithm-driven feeds amplify this further, serving increasingly personalised “ADHD traits” to users already searching for explanations.
The rise of online clinics has accelerated this trend even more. A 2023 BBC Panorama investigation exposed multiple services offering rapid assessments and same-day stimulant prescriptions following consultations that fell far short of recommended clinical standards. Key clinical steps—developmental history, collateral information or differential diagnosis—were often overlooked, making it difficult to distinguish ADHD from anxiety, chronic stress, trauma, or digital overload. As these clinics continue to proliferate, GPs are increasingly being asked to continue prescriptions initiated privately, normalising medication that may have emerged from brief or inadequate assessments.
Behind all of this sits the subtle but powerful influence of the pharmaceutical industry. Between 2012 and 2021, stimulant production increased by almost 50%, mirroring the expanded diagnostic criteria and growing adult demand. This rise has been supported by extensive marketing, funding of advocacy groups and key opinion leaders, the dissemination of “educational” materials in schools, and drug-company-funded information that heavily promotes medication over non-pharmacological approaches.
Stimulant drugs are recommended as the first-line treatment for ADHD, and for some adults they can offer improvements in focus. Examples are the methylphenidate-based stimulants such as Ritalin, which is now very widely known and used in both the US and UK. Or the amphetamine-based stimulants such as Vyvanse (in the US), known as Elvanse in the UK/EU and now also very commonly prescribed.
But like all psychoactive drugs, their effects are not risk-free. Some harms are mild, including sleep disruption, appetite loss, headaches and anxiety, while others are more serious. Research (here and here) has linked long-term use to weight loss, nutrient deficiencies, a higher likelihood of seizure, and cardiovascular strain. A meta-analysis combining results from ten clinical trials found that stimulant medications can speed up the heart by about 6 extra beats per minute—that’s more than 8,000 additional heartbeats over the course of a day plus it can also raise blood pressure slightly.
Methylphenidate, one of the most prescribed ADHD medications has also been associated with a four-fold increase in the risk of developing pre-hypertension in previously healthy young adults and a 61% higher risk for cardiac issues like arrhythmia (research here and here). These risks rise with age. A large study tracking thousands of real-world patients found that people who had just started taking stimulant medication were 40% more likely to experience a heart-related problem, such as an irregular heartbeat, stroke, or mini-stroke, in the first month of treatment. Psychotic symptoms, although rare, are well documented, and a major review reported significantly higher rates of hallucinations and paranoia in stimulant users compared with non-users.
Beyond clinical risks lies a broader social problem. As tolerance builds and the effects weaken over time, some adults may find themselves drifting toward higher doses or using stimulants for reasons unrelated to ADHD, such as productivity enhancement, emotional numbing or weight control. This pattern is increasingly visible among students and young professionals who use stimulants for “neuroenhancement,” blurring the line between treatment and performance doping.
Despite this, the most troubling issue is how little we actually know about the long-term effects of these drugs in adults. Most safety data come from short-term studies in children, leaving a large blind spot around what long-term stimulant use truly means for adult health.
While some adults genuinely require pharmacological interventions for ADHD, many simply need to correct the pressures that have gradually eroded their attention. This distinction matters, because the core symptoms of adult ADHD—difficulty focusing, disorganisation, poor time management, forgetfulness, impulsiveness, emotional volatility, low frustration tolerance and restlessness—also appear when the body and mind are under strain and overwhelm.
Chronic stress is a prime example. As well as being a risk factor, it impairs executive function, increases distractibility and intensifies emotional reactivity, closely mirroring ADHD. Several studies (here and here) show a multidirectional relationship between stress, anxiety, inflammation, and ADHD. Burnout, overwhelm and ongoing anxiety create similar cognitive patterns. Sleep deprivation and circadian disruption—also recognised risk factors—further weaken focus, memory, planning and impulse control (studies here and here).
Similarly, blood sugar instability, nutrient insufficiency and poor diet can trigger irritability, restlessness and concentration problems, with several studies (here and here) showing clear links between nutrition, behaviour and learning. Digital overload adds another layer: excessive social media use has been associated with inattention and impulsivity (studies here and here), that feel indistinguishable from ADHD.
Concerns (here and here) have also been raised that unaddressed trauma is often overlooked in ADHD assessments, even though trauma-related inattention, restlessness and emotional volatility arise from the same fronto-limbic network dysregulation seen in ADHD, blurring diagnostic boundaries.
Viewed together, it seems that almost everyone will experience ADHD-like symptoms at some point in their lives. This is precisely why proper assessment—not self-diagnosis, online questionnaires or rapid private reviews—is essential before starting stimulant medication. Before reaching for a prescription, it’s worth pausing to consider what your mind and body might actually be telling you. For many adults, attention and focus can shift significantly when underlying factors like sleep, stress, unresolved tension, nutrition or the relentless pull of digital life are gently addressed. There’s no single path, and no rush. But for some, simply tending to these foundations is where clarity and balance begins to return.
Attention difficulties are a signal that something in the body or mind is out of balance. For many adults, they are the body’s honest response to years of stress, disrupted sleep, nutrient gaps, or simply pressures of a fast-paced life. Here are some simple ways to naturally support focus, steadiness, and mental clarity:
>>> If you’re not already signed up for the ANH International weekly newsletter, sign up for free now using the SUBSCRIBE button at the top of our website – or better still – become a Pathfinder member and join the ANH-Intl tribe to enjoy benefits unique to our members.
>> Feel free to republish – just follow our Alliance for Natural Health International Re-publishing Guidelines
>>> Return to ANH International homepage
China is rapidly prioritising Alzheimer’s prevention as a major public health strategy, with an ageing population of 320 million over 60 and an estimated 20 million expected to be affected by 2030.
Our weekly roundup of the latest natural news from across the globe in one place. This week: Rob Verkerk – new podcast; Synbio ‘foods’ unsafe; Obesity isn’t a disease; Gene silencing pesticides; Updates from ANH-USA and much more…
Upcoming events, conferences, available courses and replays.
As animal health shifts toward pharma and biotech-driven interventions, basic determinants like nutrition are being sidelined—despite their immense impact on both healthspan and lifespan
